Using knowledge obtained through research into antisense oligonucleotides (ASOs) therapies for diseases such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1, we propose that using such therapy may be a promising approach for treating C9orf72 repeat expansion in c9FTD/ALS. Here, C9orf72 is linked to Duchenne muscular dystrophy.